Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
10:57:12 EDT Wed 08 May 2024
Enter Symbol
or Name
USA
CA



Q:SUPN - SUPERNUS PHARMACEUTICALS INC - http://www.supernus.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SUPN - Q0.131.20·31.260.631.23+0.080.336.81,10454430.97  31.23  30.7638.075  21.9910:37:58May 0715 min RT 2¢

Recent Trades - Last 10 of 544
Time ETExPriceChangeVolume
10:38:06Q31.2250.07550
10:37:58Q31.220.074
10:37:58Q31.220.071
10:37:58Q31.220.079
10:37:44Q31.190.041
10:37:44Q31.200.0512
10:37:44Q31.210.06100
10:37:44Q31.210.0622
10:37:44Q31.210.0622
10:37:44Q31.210.065

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-07 10:00U:SUPNNews ReleaseM8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree(TM) (Viloxazine XR) in Latin America
2024-05-01 08:01U:SUPNNews ReleaseBusy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
2024-04-24 16:06U:SUPNNews ReleaseSupernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
2024-04-08 08:00U:SUPNNews ReleaseSupernus Provides Regulatory Update for SPN-830
2024-03-06 16:31U:SUPNNews ReleaseSupernus to Participate in Two Upcoming Investor Conferences
2024-02-28 16:30U:SUPNNews ReleaseSupernus to Participate in the TD Cowen 44th Annual Healthcare Conference
2024-02-27 16:06U:SUPNNews ReleaseSupernus Announces Fourth Quarter and Full Year 2023 Financial Results
2024-02-13 16:05U:SUPNNews ReleaseSupernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
2024-02-05 08:31U:SUPNNews ReleaseSupernus Wins Infringement and Validity Case on Trokendi XR ‚ ® against Torrent
2023-12-19 07:30U:SUPNNews ReleaseKnight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree ‚ ® (viloxazine) in Canada
2023-11-08 16:06U:SUPNNews ReleaseSupernus Announces Third Quarter 2023 Financial Results
2023-11-07 16:31U:SUPNNews ReleaseSupernus to Participate in the Jefferies London Healthcare Conference
2023-11-02 07:00U:SUPNNews ReleaseSupernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
2023-10-25 16:16U:SUPNNews ReleaseSupernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 8, 2023
2023-10-16 17:34U:SUPNNews ReleaseJay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree ‚ ® Journey
2023-10-09 16:45U:SUPNNews ReleaseSupernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
2023-09-27 16:16U:SUPNNews ReleaseSupernus Pharmaceuticals Announces Webcast of R&D Day to be Held ‚  on October 18, 2023 in New York City
2023-09-09 20:01U:SUPNNews ReleaseSupernus Announces New Qelbree ‚ ® Data Showing Improvement in ADHD Symptoms
2023-08-31 17:30U:SUPNNews ReleaseSupernus to Participate in the Wells Fargo Healthcare Conference
2023-08-21 09:01U:SUPNNews ReleaseBethany L. Sensenig Joins Supernus ¢ € ™ Board of Directors